SCHEMBL18153380

SCHEMBL18153380

Cc1ccc(Oc2cc(C)nc(N3CCN(C(=O)OC(C)(C)C)CC3)n2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.53
KMT2A Q03164 7/20 0.53
MEN1 O00255 6/20 0.53
CYP2C19 P33261 3/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2C9 P11712 2/20 0.47
TSHR P16473 2/20 0.47
HSD17B10 Q99714 2/20 0.47
HTT P42858 1/20 0.47
LMNA P02545 1/20 0.47
ALDH1A1 P00352 3/20 0.46
CYP2D6 P10635 1/20 0.46
ATM Q13315 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
GPR119 Q8TDV5 5/20 0.46
GBA1 P04062 1/20 0.45
GAA P10253 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
SLC2A1 P11166 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18087219 0.83 ALDH1A1 (0.57) SMN1; SMN2KMT2AMEN1TSHRHSD17B10
SCHEMBL18063491 0.81 MAPT (0.48) SMN1; SMN2KMT2AMEN1TSHRHTT
SCHEMBL18162356 0.81 S1PR2 (0.48) LMNAMAPTGPR119SLC2A1ACHE
SCHEMBL21744919 0.81 MEN1 (0.44) SMN1; SMN2KMT2AMEN1ALDH1A1MAPT
SCHEMBL18162598 0.80 S1PR2 (0.49) LMNAGPR119SLC2A1ACHE
SCHEMBL20042188 0.80 MAPT (0.54) SMN1; SMN2KMT2AMEN1TSHRLMNA
SCHEMBL18063521 0.80 MAPT (0.58) SMN1; SMN2KMT2AMEN1CYP2C19TSHR
SCHEMBL18153320 0.80 MEN1 (0.45) SMN1; SMN2KMT2AMEN1CYP2C19HSD17B10
SCHEMBL16836632 0.79 MEN1 (0.53) KMT2AMEN1ALDH1A1MAPTHPGD
SCHEMBL18153377 0.79 S1PR2 (0.46) LMNAGPR119SLC2A1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3283472-B1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS UNIV INDIANA RES & TECH CORP (US) 2021-04-14 EP disclosed
US-10273228-B2 Hepatitis B viral assembly effectors INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2019-04-30 US disclosed
US-20180099952-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-04-12 US disclosed
US-20180099952-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-04-12 US disclosed
EP-3283472-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS Indiana University Research&Technology Corporation (US) 2018-02-21 EP disclosed
WO-2016168619-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2016-10-20 WO disclosed
WO-2016168619-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2016-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180099952-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS HAVCR2, MAVS, HCCS SMN1; SMN2 4578/4885KMT2A 4450/4885MEN1 4380/4885
US-10273228-B2 Hepatitis B viral assembly effectors HAVCR2, MAVS, HCCS SMN1; SMN2 4578/4885KMT2A 4450/4885MEN1 4380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.